Download to read offline
More Related Content
Similar to cytomegalovirus , better understanding.pptx
cytomegalovirus , better understanding.pptx
- 3. What Is Cytomegalovirus(CMV)?
- 4.
- 5. CMV: The MostCommon Virus Few People Have Heard Of
- 6. CMV Life Cycleand Pathogenesis
- 7. CMV Burden andEpidemiology
- 8. CMV Establishes LifelongLatency
- 9. Clinical Manifestations ofCMV Vary Based on Immune Status
- 10. CMV Is TransmittedFrom Person to Person Through Bodily Fluids
- 11. Main Sources ofCMV Acquisition
- 12. Seroprevalence of CMVVaries by Population and Assessment
- 13. CMV Seroprevalence IncreasesWith Age
- 14. Risk Factors forCMV Seropositivity
- 15. CMV Infection DuringPregnancy
- 16. Estimated Global Prevalenceof cCMV
- 17. cCMV Prevalence Variesby Geographic Region
- 18. Regional and MaternalFactors That Correlate With cCMV Rate
- 19. cCMV Prevalence Variesby Race/Ethnicity and SES
- 20. cCMV Risk DuringPregnancy
- 21. How CMV DiffersFrom Other Congenitally Transmitted Viruses
- 22. cCMV Risk WithPrimary vs Nonprimary CMV Infection
- 23. cCMV Risk WithPrimary vs Nonprimary CMV Infection
- 24. cCMV Risk WithPrimary vs Nonprimary CMV Infection
- 25. Risks of CMVInfection During Pregnancy
- 26. Infants and YoungChildren Are Often Carriers of CMV
- 27. Maternal CMV DiseaseIs Difficult to Diagnose
- 28. Maternal CMV DiseaseIs Difficult to Diagnose
- 29. Imaging Can HelpIdentify a Fetus With cCMV
- 30. Gestational Age atMaternal CMV Acquisition Affects Vertical Transmission Risk and Predicts cCMV Severity
- 31. Gestational Age atMaternal CMV Acquisition Affects Vertical Transmission Risk and Predicts cCMV Severity
- 32. cCMV Sequelae inFetuses and Children
- 33. Prognostic Assessments ina CMV-Infected Fetus
- 34. Findings Consistent Witha Fetal CMV Infection
- 35. Findings Consistent Witha Fetal CMV Infection
- 36. cCMV Manifests aSpectrum of Outcomes
- 37. cCMV Is BroadlyCategorized as Symptomatic or Asymptomatic
- 38. cCMV Is BroadlyCategorized as Symptomatic or Asymptomatic
- 39. cCMV Can CauseLifelong Morbidity Regardless of Whether Neonates Are Symptomatic or Asymptomatic at Birth
- 40. cCMV Can CauseLifelong Morbidity Regardless of Whether Neonates Are Symptomatic or Asymptomatic at Birth
- 41. The Role ofAntiviral Treatment in cCMV
- 42. Benefits and Risks/Limitationsof Antiviral Use Observations From Two Phase 3 Randomized Trials in cCMV
- 43. Benefits and Risks/Limitationsof Antiviral Use Observations From Two Phase 3 Randomized Trials in cCMV
- 44. Benefits and Risks/Limitationsof Antiviral Use Observations From Two Phase 3 Randomized Trials in cCMV
- 45. Benefits and Risks/Limitationsof Antiviral Use Observations From Two Phase 3 Randomized Trials in cCMV
- 46. Reducing the Prevalenceof cCMV
- 47. Strategies for Reducingthe Burden of cCMV
- 48. Clinical Studies ofHyperimmune Globulin (HIG) to Prevent cCMV
- 49. Antivirals to PreventIntrauterine Transmission of CMV
- 50. Routine Prenatal SerologyTesting for CMV Is Not Advised
- 51. Hygiene Practices CanHelp Prevent Maternal CMV Infection
- 52. Other Recommendations toReduce the Burden of cCMV
- 53.
- 54. Platforms of CandidateCMV Vaccines in Clinical Trials
- 55. Candidate CMV VaccinesWith Partial Efficacy in Clinical Trials
- 56. Improving Efficacy ofCandidate CMV Vaccines
- 57. Improving Efficacy ofCandidate CMV Vaccines
- 58. Improving Efficacy ofCandidate CMV Vaccines
- 59. Improving Efficacy ofCandidate CMV Vaccines
- 60. Summary of CurrentPrevention Strategies
- 61. The CMV "KnowledgeVaccine" or "Information Immunization"
- 62. The First ComponentIs an Ounce of Awareness
- 63. Add in These3 Hygiene Practices for Pregnant Women During Interactions With Young Children
- 64.